Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About MCB
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Molecular and Cellular Biology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About MCB
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Articles

Therapeutic Levels of the Hydroxmethylglutaryl-Coenzyme A Reductase Inhibitor Lovastatin Activate Ras Signaling via Phospholipase D2

Kwang-jin Cho, Michelle M. Hill, Sravanthi Chigurupati, Guangwei Du, Robert G. Parton, John F. Hancock
Kwang-jin Cho
1Department of Integrative Biology and Pharmacology, The University of Texas Medical School—Houston, 6431 Fannin Street, Houston, Texas 77030
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle M. Hill
2The University of Queensland, Diamantina Institute, Woolloongabba, Queensland 4102, Australia
3The University of Queensland, Institute for Molecular Bioscience, St Lucia, Queensland 4072, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sravanthi Chigurupati
1Department of Integrative Biology and Pharmacology, The University of Texas Medical School—Houston, 6431 Fannin Street, Houston, Texas 77030
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guangwei Du
1Department of Integrative Biology and Pharmacology, The University of Texas Medical School—Houston, 6431 Fannin Street, Houston, Texas 77030
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert G. Parton
3The University of Queensland, Institute for Molecular Bioscience, St Lucia, Queensland 4072, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John F. Hancock
1Department of Integrative Biology and Pharmacology, The University of Texas Medical School—Houston, 6431 Fannin Street, Houston, Texas 77030
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: John.F.Hancock@uth.tmc.edu
DOI: 10.1128/MCB.00989-10
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIG. 1.
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Effect of therapeutic levels of lovastatin on cellular cholesterol and Ras prenylation. BHK cells (a) and HUVECs (c) were cultured in growth medium containing 10% DCS, 10% FCS, or 10% LPDS in the presence of lovastatin for 48 h. BHK cells (b) and HUVECs (d) were cultured in growth medium containing 10% LPDS supplemented with 100 or 240 mg/dl purified LDL-C. Total cellular cholesterol levels were measured. The graphs show means ± standard errors of the means (SEM) for 3 independent experiments. Differences between lovastatin-untreated and lovastatin-treated cells under each culture condition in panels a to d were assessed using one-way analysis-of-variance (ANOVA) tests, and significant differences are indicated (*, P < 0.05). (e) HUVECs were treated with various concentrations of lovastatin in the presence of 10% LPDS for 48 h. Control cells were cultured in standard growth medium containing 10% FCS. Cells were lysed in 1% Triton X-114 and lysates separated into detergent-enriched (Det.) and aqueous (Aq) phases by warming. After separation of the two phases by centrifugation, a 1× volume of the detergent-enriched phase (20 μl) containing hydrophobic proteins and a 2× volume of the aqueous phase (40 μl) containing hydrophilic proteins were blotted with an anti-pan Ras, anti-Rho, or anti-Rap1A/B antibody. A representative blot and mean percentages of the detergent fraction for 3 independent experiments are shown.

  • FIG. 2.
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Therapeutic levels of lovastatin modulate ERK and Akt activation. BHK cells (a and e) and HUVECs (b and f) were cultured in growth medium containing 10% DCS, 10% FCS, or 10% LPDS in the presence of lovastatin for 48 h. Cell lysates were assayed for ppERK or pAkt (S473) using phospho-specific antibodies and quantitative immunoblotting. The graphs show mean levels of ppERK or pAkt, relative to levels in cells grown in 10% DCS or FCS without lovastatin, ± SEM for 3 independent experiments. Differences between lovastatin-untreated and lovastatin-treated cells under each culture condition were assessed using one-way ANOVA tests, and significant differences are indicated (*, P < 0.05). (c and d) Total cellular cholesterol levels in Fig. 1 were plotted against the corresponding mean ppERK levels shown in panels a and b. The line was fitted by linear regression.

  • FIG. 3.
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Activation of Ras signaling by lovastatin is a consequence of cholesterol depletion. (a) BHK cells treated with lovastatin in the presence of 10% LPDS for 48 h were incubated with 25 μM water-soluble free cholesterol (+CHOL) or vehicle (CON) at 37°C for 20 min and harvested. Total Ras-GTP levels were measured in an RBD pulldown assay and compared to the level for cells grown in DCS. The graph shows mean fold increases in Ras-GTP levels ± SEM for 3 independent experiments. Differences between lovastatin-treated and control cells in the presence and absence of free cholesterol were assessed using one-way ANOVA tests. Significant differences are indicated (*, P < 0.05). A representative blot is shown. (b) BHK cells were treated with various concentrations of lovastatin in the presence of 10% LPDS for 48 h. Control cells were cultured in standard growth medium containing 10% DCS. H-, N-, and K-Ras-GTP loadings were measured using an RBD pulldown assay. A blot representative of 4 (H- and N-Ras) or 3 (K-Ras) independent experiments is shown.

  • FIG. 4.
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    EGF receptor expression is downregulated by lovastatin treatment. BHK cells were treated with lovastatin in the presence of 10% LPDS for 48 h. Control cells were cultured in standard growth medium containing 10% DCS. Total EGFR and phospho-EGFR (Y1068) levels were measured by quantitative immunoblotting. The graph in panel a shows mean EGFR and pEGFR levels ± SEM relative to levels in cells grown in control medium. An immunoblot representative of 3 independent experiments is also shown. ERK2 levels are used as a loading control. The specific activity of the EGFR (b) was estimated as the normalized ratio of phospho-EGFR to total EGFR using values obtained from panel a. For panels a and b, differences between lovastatin-treated and control cells were assessed using one-way ANOVA tests. Significant differences are indicated (*, P < 0.05; **, P < 0.01). (c) BHK cells were cultured in growth medium containing 10% DCS or 10% LPDS in the presence of lovastatin. Note that these growth conditions replicate those in Fig. 1a, where the presence of DCS maintains normal cell cholesterol levels in the presence of lovastatin. Total EGFR levels were measured by quantitative immunoblotting. The graph shows mean EGFR levels ± SEM relative to levels in cells grown in DCS. Differences between cells cultured in DCS and LPDS at each concentration of lovastatin were assessed using two-tailed t tests. Significant differences are indicated (*, P < 0.05; **, P < 0.01). An immunoblot representative of 3 independent experiments is also shown. ERK2 levels are used as a loading control.

  • FIG. 5.
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    PLD activity is required for Ras and ERK activation in response to cholesterol depletion. BHK cells were treated with lovastatin for 48 h in the presence of 10% LPDS. Control cells were cultured in 10% DCS. For the final 4 h of incubation, n-butanol (BtOH) or t-BtOH was added to the growth medium to give a final concentration of 1% (vol/vol). Ras-GTP levels were measured using an RBD pulldown assay (a) and ppERK levels measured by quantitative immunoblotting (b). A representative blot for each experiment is shown, with total Ras and ERK2 used as loading controls. Growth in n-butanol inhibits phosphatidic acid production by PLD, whereas growth in t-butanol does not (Materials and Methods). The graphs show mean levels ± SEM for 3 independent experiments. Differences between lovastatin-treated and control cells grown in n-BtOH or t-BtOH were assessed using one-way ANOVA tests. Significant differences are indicated (*, P < 0.05; **, P < 0.01; ***, P < 0.001).

  • FIG. 6.
    • Open in new tab
    • Download powerpoint
    FIG. 6.

    Cholesterol depletion stimulates phosphatidic acid production at the plasma membrane. (a) BHK cells were treated with lovastatin for 32 h in the presence of 10% LPDS. Control cells were cultured in standard growth medium containing 10% DCS. In each case, cells were then labeled with [3H]palmitate for a further 16 h. Cellular lipids were extracted and resolved by TLC. The graph shows mean phosphatidic acid (PA) level as a percentage of total phospholipids ± SEM for 3 independent experiments. Differences between lovastatin-treated and control cells were assessed using one-way ANOVA tests, and significant differences are indicated (*, P < 0.05). (b) Intact plasma membrane sheets were generated from BHK cells expressing mGFP-NES-Spo20 and cultured for 48 h in 300 nM lovastatin (LOV) in 10% LPDS or in normal medium containing 10% DCS. Plasma membrane sheets were labeled with anti-GFP antibody conjugated to 5-nm gold particles. The graph shows the mean number of gold particles/μm2 (± SEM). Differences between lovastatin-treated and control cells were assessed using two-tailed t tests. Significant differences are indicated (***, P < 0.001). (c) BHK cells coexpressing mGFP-NES-Spo20 and mRFP-NES-Spo20 or mRFP were cultured in normal medium containing 10% DCS or 10% LPDS with 300 nM lovastatin for 48 h. Cells were imaged in a wide-field FLIM microscope. The graph represents the mean fluorescence lifetime of GFP (± SEM). Differences between lovastatin-treated and control cells were assessed using two-tailed t tests. Significant differences are indicated. BHK cells expressing mGFP-NES-Spo20 alone cultured in standard growth medium was used to determine initial mGFP lifetime. In this assay a reduction in mGFP lifetime indicates increased FRET between mGFP and mRFP.

  • FIG. 7.
    • Open in new tab
    • Download powerpoint
    FIG. 7.

    Lovastatin-induced EGFR downregulation is blocked by EGFR inhibition. BHK cells were cultured for 48 h in normal medium containing 10% DCS or 10% LPDS in the presence of lovastatin with or without 0.5 μM AG1478. Cell lysates were assayed for total EGFR (a and b) or ppERK (c and d). The graphs show mean levels of total EGFR or ppERK, relative to levels in AG1478-treated cells grown with lovastatin under each culture condition, ± SEM for 3 independent experiments. Differences between AG1478-untreated and AG1478-treated cells at each lovastatin concentration were assessed using two-tailed t tests. Significant differences are indicated (*, P < 0.05; **, P < 0.01; ***, P < 0.001). (e) BHK cells were cultured for 48 h in 10% LPDS plus 300 nM lovastatin or 10% DCS plus 300 nM lovastatin with or without 0.5 μM AG1478. These growth conditions replicate those represented in Fig. 1a, where the presence of DCS maintains normal cell cholesterol levels in the presence of lovastatin. Control cells were cultured in standard growth medium containing 10% DCS. Total Ras-GTP levels were measured. The graphs show means ± SEM of results from 3 independent experiments. Differences between lovastatin-treated and control cells were assessed using one-way ANOVA tests. Significant differences are indicated (**, P < 0.01).

  • FIG. 8.
    • Open in new tab
    • Download powerpoint
    FIG. 8.

    Lovastatin-induced activation of PLD2 and EGFR are independent events. BHK cells stably expressing GFP-mPLD2 WT, GFP-mPLD2 K758R, or empty pEF6 vector were treated with 300 nM lovastatin for 48 h. Control cells were cultured in standard growth medium containing 10% DCS. Ras-GTP (a) ppERK (b) and pAkt (S473) (c) levels were measured by quantitative immunoblotting. The graphs show mean values ± SEM for 3 independent experiments. The effect of ectopic expression of mPLD2 WT or mPLD2 K758R with lovastatin against pEF6 was assessed using one-way ANOVA tests. Significant differences are indicated (*, P < 0.05; **, P < 0.01; ***, P < 0.001). (d) BHK cells stably expressing GFP-mPLD2 K758R or empty pEF6 vector were treated for 48 h with lovastatin in 10% LPDS. Cell lysates were assayed for total EGFR by quantitative immunoblotting. The graphs show means ± SEM for 3 independent experiments. No significant difference in EGFR levels between pEF6-transfected and GFP-mPLD2 K758R-expressing cells were detected using two-tailed t tests.

PreviousNext
Back to top
Download PDF
Citation Tools
Therapeutic Levels of the Hydroxmethylglutaryl-Coenzyme A Reductase Inhibitor Lovastatin Activate Ras Signaling via Phospholipase D2
Kwang-jin Cho, Michelle M. Hill, Sravanthi Chigurupati, Guangwei Du, Robert G. Parton, John F. Hancock
Molecular and Cellular Biology Feb 2011, 31 (6) 1110-1120; DOI: 10.1128/MCB.00989-10

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Molecular and Cellular Biology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Therapeutic Levels of the Hydroxmethylglutaryl-Coenzyme A Reductase Inhibitor Lovastatin Activate Ras Signaling via Phospholipase D2
(Your Name) has forwarded a page to you from Molecular and Cellular Biology
(Your Name) thought you would be interested in this article in Molecular and Cellular Biology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Therapeutic Levels of the Hydroxmethylglutaryl-Coenzyme A Reductase Inhibitor Lovastatin Activate Ras Signaling via Phospholipase D2
Kwang-jin Cho, Michelle M. Hill, Sravanthi Chigurupati, Guangwei Du, Robert G. Parton, John F. Hancock
Molecular and Cellular Biology Feb 2011, 31 (6) 1110-1120; DOI: 10.1128/MCB.00989-10
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About MCB
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #MCBJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0270-7306; Online ISSN: 1098-5549